South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic ...
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
The South Korean firm just agreed to buy Biogen out of their biosimilar joint venture – Samsung Bioepis – for $2.3 billion. The two companies have been partnered on Samsung Bioepis for the ...
Kim Kyung-Ah, CEO of Samsung Bioepis, stated in her New Year's address on the 2nd, 'The U.S. launch of biosimilar drugs, ...
Korea’s Samsung Bioepis has begun clinical development of its first ever novel biologic – a protein intended to treat severe acute pancreatitis. A joint venture between Samsung and Biogen ...
and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback